UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 24, 2021

 

LIFEMD, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-39785   76-0238453

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

800 Third Avenue, Suite 2800

New York, NY 10022

(Address of principal executive offices, including zip code)

 

(866) 351-5907

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

[  ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   LFMD   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 24, 2021, the shareholders of LifeMD Inc. (the “Company”) approved an amendment to the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”) to increase the number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 24, 2021, the Company held an annual meeting of stockholders (the “Annual Meeting”). A majority in interest of all stock issued, outstanding and entitled to vote at the Annual Meeting were present in person or by proxy, thereby constituting a quorum.

 

The matters voted upon and approved by the Company’s stockholders were:

 

  (1) The election of eight directors to serve until the next annual meeting of stockholders and until their respective successors shall have been duly elected and qualified (“Proposal 1”).
  (2) The approval of an amendment to the “2020 Plan to increase the number of shares of the Company’s common stock available for issuance under the 2020 Plan by 1,500,000 shares (“Proposal 2”).
  (3) The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (“Proposal 3”).
  (4) The recommendation, on a non-binding advisory basis, on the frequency of future advisory votes on the compensation of the Company’s named executive officers (“Proposal 4”).
  (5) The ratification of the selection of Friedman LLP as LifeMD’s independent registered public accounting firm for the fiscal year ending December 31, 2021 (“Proposal 5”).

 

The following is a summary of the voting results for each matter presented to the shareholders:

 

Proposal 1:

 

Director’s Name   Votes For   Votes Withheld   Broker Non-Votes
Justin Schreiber   12,433,875   39,147   5,736,727
Stefan Galluppi   12,435,496   37,526   5,736,727
John R. Strawn, Jr.   10,780,081   1,692,941   5,736,727
Happy Walters   12,425,590   47,432   5,736,727
Bertrand Velge   11,009,506   1,463,516   5,736,727
Dr. Joseph V. DiTrolio   11,905,775   567,247   5,736,727
Dr. Eleanor C. Mariano   12,433,241   39,781   5,736,727
Roberto Simon   12,433,902   39,120   5,736,727

 

Proposal 2:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes
10,378,379   1,886,624   208,019   5,736,727

 

Proposal 3:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes
12,272,487   121,337   79,198   5,736,727

 

Proposal 4:

 

One Year
Votes For
  Two Years
Votes For
  Three Years
Votes For
  Votes
Abstained
  Broker Non-Votes
2,082,424   80,554   10,257,592   52,452   5,736,727

 

Proposal 5:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes
18,119,574   16,276   73,899   N/A

 

All Proposals were approved. We have determined to hold an advisory vote every three years on executive compensation, based on our stockholders’ support for this alternative in Proposal 4.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LIFEMD, INC.
       
Dated: June 29, 2021 By: /s/ Justin Schreiber
      Justin Schreiber
      Chief Executive Officer

 

 

LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more LifeMD Charts.
LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more LifeMD Charts.